These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 619863)
1. Testing the lipid hypothesis. Clinical trials. Rifkind BM; Levy RI Arch Surg; 1978 Jan; 113(1):80-3. PubMed ID: 619863 [TBL] [Abstract][Full Text] [Related]
2. Dietary and serum lipids in the multifactorial etiology of atherosclerosis. Stamler J Arch Surg; 1978 Jan; 113(1):21-5. PubMed ID: 202219 [TBL] [Abstract][Full Text] [Related]
3. A perspective on hyperlipidemia: concepts of management in the prevention of coronary artery disease. Amsterdam EA; Deedwania PC Am J Med; 1998 Jul; 105(1A):69S-74S. PubMed ID: 9707271 [TBL] [Abstract][Full Text] [Related]
4. Regression of coronary atherosclerosis: an achievable goal? Review of results from recent clinical trials. Waters D; Lespérance J Am J Med; 1991 Jul; 91(1B):10S-17S. PubMed ID: 1867231 [TBL] [Abstract][Full Text] [Related]
5. Rationale for treatment. Gotto AM Am J Med; 1991 Jul; 91(1B):31S-36S. PubMed ID: 1867234 [TBL] [Abstract][Full Text] [Related]
6. Cholesterol: precursor to many lipid disorders. Jones PH Am J Manag Care; 2001 Aug; 7(9 Suppl):S289-98. PubMed ID: 11517815 [TBL] [Abstract][Full Text] [Related]
8. Two follow-up studies of preventive lipid-lowering trials support the validity of the lipid hypothesis. Olsson AG J Intern Med; 1994 Jan; 235(1):1-4. PubMed ID: 8283155 [No Abstract] [Full Text] [Related]
9. Role of risk factor management in progression and regression of coronary and femoral artery atherosclerosis. Glueck CJ Am J Cardiol; 1986 May; 57(14):35G-41G. PubMed ID: 3521250 [TBL] [Abstract][Full Text] [Related]
13. [Treatment of lipid disorders for coronary heart disease prevention according to International Atherosclerosis Society recommendations]. Idzior-Waluś B Przegl Lek; 1999; 56(5):372-6. PubMed ID: 10554575 [TBL] [Abstract][Full Text] [Related]
14. C-reactive protein in 2005. Interview by Peter C. Block. Ridker PM J Am Coll Cardiol; 2005 Jul; 46(1):CS2-5. PubMed ID: 16007748 [TBL] [Abstract][Full Text] [Related]
15. Is aggressive lipid lowering as effective as angioplasty in some cardiac patients? Drown DJ Prog Cardiovasc Nurs; 1999; 14(4):160-1. PubMed ID: 10689731 [No Abstract] [Full Text] [Related]
16. Prevention of coronary heart-disease. Shaper AG Lancet; 1976 Nov; 2(7996):1203-4. PubMed ID: 63029 [No Abstract] [Full Text] [Related]
17. "Metabolic syndrome" targeted in new US cholesterol guidelines. Larkin M Lancet; 2001 May; 357(9268):1594. PubMed ID: 11377654 [No Abstract] [Full Text] [Related]
18. Impact of multiple risk factors on coronary artery disease: beyond total cholesterol. Introduction. Gotto AM Am J Cardiol; 1998 Nov; 82(9A):1Q-2Q. PubMed ID: 9819097 [No Abstract] [Full Text] [Related]
19. Interactions of hyperlipidemia, hypertension and obesity as coronary risk factors. Alexander JK Triangle; 1975; 14(1):1-8. PubMed ID: 1099746 [No Abstract] [Full Text] [Related]
20. Clinical inquiries. What is the best strategy for monitoring the lipid-lowering effects of medical therapy used for the primary prevention of coronary artery disease (CAD)? Sherrod JP; Krist A J Fam Pract; 2001 Nov; 50(11):928. PubMed ID: 11711006 [No Abstract] [Full Text] [Related] [Next] [New Search]